======================================================================
GLP-1 RECEPTOR AGONISTS ADVERSE EVENTS - EDA SUMMARY REPORT
======================================================================
Generated: 2026-02-03 17:33:34

DATA OVERVIEW
----------------------------------------
Total unique adverse event reports: 20,307
Total reaction-level observations: 87,154
Date range: 2004-02-13 to 2025-12-31
Years covered: 2004 - 2025

REPORTS BY DRUG
----------------------------------------
  Semaglutide      6,027 ( 29.7%)
  Liraglutide      5,082 ( 25.0%)
  Exenatide        4,913 ( 24.2%)
  Dulaglutide      2,181 ( 10.7%)
  Tirzepatide      2,104 ( 10.4%)

SERIOUSNESS DISTRIBUTION
----------------------------------------
  Serious events: 12,233 (60.2%)
  Non-serious:    8,074 (39.8%)

  Breakdown by outcome:
    Deaths:            660
    Life-threatening:  1,365
    Hospitalizations:  6,670
    Disabling:         393

TOP 20 MOST FREQUENT ADVERSE EVENTS
----------------------------------------
   1. Nausea                                    2,131
   2. Vomiting                                  1,530
   3. Diarrhoea                                 1,257
   4. NAUSEA                                    1,183
   5. WEIGHT DECREASED                            997
   6. Dyspnoea                                    853
   7. Weight decreased                            780
   8. Off label use                               776
   9. Blood glucose increased                     774
  10. BLOOD GLUCOSE INCREASED                     773
  11. Drug ineffective                            741
  12. Fatigue                                     732
  13. Acute kidney injury                         694
  14. Headache                                    654
  15. DECREASED APPETITE                          613
  16. Decreased appetite                          600
  17. Dizziness                                   589
  18. Constipation                                543
  19. Malaise                                     534
  20. Abdominal pain                              512

SIGNALS OF INTEREST
----------------------------------------

GASTROPARESIS/DELAYED GASTRIC EMPTYING:
  PRESENT - 3 unique reports
    Tirzepatide: 1
    Liraglutide: 1
    Exenatide: 1

THYROID NEOPLASM/DISORDERS:
  PRESENT - 380 unique reports
    Liraglutide: 219
    Semaglutide: 68
    Exenatide: 41
    Tirzepatide: 27
    Dulaglutide: 25

PATIENT DEMOGRAPHICS
----------------------------------------
  Female: 10,854 (53.4%)
  Male: 7,848 (38.6%)
  Unknown: 1,605 (7.9%)

  Age statistics (n=15,686):
    Mean: 58.5 years
    Median: 61.0 years
    Range: 0 - 104 years

OUTPUT FILES
----------------------------------------
  Cleaned data: workflow/data/glp1_cleaned.parquet
  Reports over time: figures/reports_over_time.png
  Top adverse events: figures/top_adverse_events.png
  This summary: results/eda_summary.txt

======================================================================
END OF REPORT
======================================================================